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Abstract Leukotriene A4 (LTA4) hydrolase is essential for the
conversion of LTA4 to LTB4, an inflammatory lipid mediator.
We investigated whether LTA4 hydrolase was regulated in the
heart by angiotensin II (ang II) infusion. Continuous ang II
infusion via an osmotic minipump for up to 7 days upregulated
mRNA and protein levels of LTA4 hydrolase (V3.5-fold of
control) in the heart in a pressor-dependent manner. Immuno-
histochemistry demonstrated intense LTA4 hydrolase staining in
the myofibroblast as well as migrated monocytes/macrophages.
These data suggest that the cardiac LTA4 hydrolase-LTB4
system plays a positive role in the promotion of cardiac
inflammation in hypertension.
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1. Introduction
Leukotrienes (LTs) are biologically active lipids that are
synthesized and released from leukocytes and non-leukocytic
tissue. The pathway of LT synthesis is initialized by the re-
lease of arachidonic acid from membrane phospholipids by
the action of phospholipase A2 (PLA2). Liberated arachidonic
acid is then converted to LTA4 through 5-hydroperoxy-
6,8,11,14-eicosatetraenoic acid by the enzyme 5-lipoxygenase
(5LO) [1] with 5LO activating protein. LTA4 is further con-
verted to LTB4 by the action of LTA4 hydrolase or is con-
jugated to form LTC4 [2]. Although 5LO is thought to be
exclusively present in leukocytes, exogenously produced
LTA4 can be metabolized to LTB4 by the action of LTA4
hydrolase [3,4], in non-leukocytes via transcellular LTA4 me-
tabolism. Interestingly, exposure to substrate inactivates
LTA4 hydrolase as a consequence of the covalent binding of
LTA4 to the active site [5], implicating that LTA4-LTB4 con-
version is a self-limiting reaction unless LTA4 hydrolase is
synthesized de novo.
LTs are implicated in in£ammatory and immediate hyper-
sensitive responses. Of these, LTB4 has the strongest chemo-
tactic and chemoattracting activities on leukocytes and has
been postulated to play an important role in a variety of
pathological conditions including rheumatoid arthritis, psori-
asis and in£ammatory bowel disease [6]. We have previously
demonstrated that LTA4 hydrolase is ubiquitously expressed
in many tissues including heart, aorta, lung, intestinal tracts,
liver [7] and kidney [8], as well as leukocytes. The wide dis-
tribution of LTA4 hydrolase suggests a positive role of these
non-leukocytic tissues in the generation of LTB4 for the re-
cruitment of leukocytes into the in£ammatory lesion.
It has been shown that angiotensin II (ang II) administra-
tion induces a cardiac in£ammatory response [9]. We hypothe-
sized that the expression of LTA4 hydrolase may be upregu-
lated in the heart of rats receiving ang II. In this study, we
demonstrate that LTA4 hydrolase expression is upregulated in
the heart of ang II-induced hypertensive rats and that myo¢-
broblasts as well as migrated leukocytes in the in£ammatory
lesions show intense expression of this molecule.
2. Materials and methods
2.1. Animal models
To produce a rat hypertension model, an osmotic minipump (Alzet
model 2001) (Alza) was subcutaneously implanted into Sprague-Daw-
ley rats (Nippon Bio-Supply Center) as described previously [10].
Val5-ang II (Sigma) was infused at a rate of 0.7 mg/kg/day for up
to 7 days unless otherwise described. Systolic blood pressure and heart
rate were measured in conscious rats by tail-cu¡ plethysmography
(UR-5000) (Ueda Seisakusyo). In some experiments, the selective
AT1 receptor antagonist TA-606 (10 mg/kg/day) (a kind gift from
Discovery Research Laboratory, Tanabe Seiyaku) or the non-speci¢c
vasodilator hydralazine (15 mg/kg/day) (Sigma) was given in the
drinking water, beginning 2 days before pump implantation and dur-
ing ang II infusion.
2.2. RNA isolation and Northern blot analysis
Total RNA was isolated from the homogenized heart by the acid
guanidinium thiocyanate-phenol chloroform method using Isogen
(WAKO). Human LTA4 hydrolase cDNA was labelled with [K-32P]-
dCTP (DuPont NEN) using commercial kits (Nippon Gene). Hybrid-
ization was performed as described previously [10]. Hybridized bands
were visualized and quanti¢ed using a bio-imaging analyzer (BAS
2000, Fuji Photo Film) and the band density was normalized to the
intensity of ethidium bromide-stained 28S and 18S ribosomal RNA.
2.3. Protein puri¢cation and Western blot analysis
Protein was isolated by homogenizing samples in the lysis bu¡er (50
mmol/l HEPES, 5 mmol/l ethylenediaminetetraacetic acid (EDTA)
and 50 mmol/l NaCl; pH 7.5) containing protease inhibitors (10 Wg/
ml aprotinin, 1 mmol/l PMSF and 10 Wg/ml leupeptin). Blots were
incubated with a⁄nity-puri¢ed anti-human LTA4 hydrolase antibody
at a concentration of 2 Wg/ml and subsequently incubated with horse-
radish-conjugated secondary antibody (Jackson ImmunoResearch) at
a 1/2000 dilution. The ECL Western blotting system (Amersham Life
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Sciences) was used for detection. Bands were visualized and quanti¢ed
using a lumino-analyzer (LAS-1000, Fuji Photo Film).
2.4. Immunohistochemistry
Immunohistochemistry was performed as described previously [11].
Brie£y, depara⁄nized sections were preincubated with 10% horse se-
rum. Sections were then incubated with antibodies against macro-
phage/monocyte (ED1; Chemicon International, Temecula, CA,
USA), human K-smooth muscle actin (K-SM actin, Sigma) and human
LTA4 hydrolase at 1/200, 1/1000 and 1/75 dilutions, respectively, at
37‡C for 1 h. Next, the slides were washed and incubated with bio-
tinylated secondary antibodies. After treating the slides with Elite
ABC kit (Vector Laboratories), antigens were visualized with the
3,3-diaminobenzidine tetrahydrochloride (DAKO) system. Counter-
staining was performed with methyl green (DAKO).
2.5. LTA4 hydrolase assay
LTA4 hydrolase activity was measured as described previously with
minor modi¢cations [8]. Frozen samples were homogenized with three
volumes of phosphate-bu¡ered saline containing 10 mmol/l EDTA
and homogenized using a glass grinder. Then, 40 Wl of 100 000Ug
supernatant was mixed with 10 Wl of 0.1 mol/l Tris-HCl bu¡er (pH
7.6). After pre-warming at 37‡C, 1 Wg of LTA4 in ethanol was added
to the samples and reaction was stopped after 1 min. After centrifu-
gation at 10 000Ug, the samples were injected onto high pressure
liquid chromatography. The conditions were as follows: column,
TSK-ODS 80TM, 0.46U15 cm; column temperature, 35‡C; UV mon-
itor and 270 nm. Prostaglandin B2 (PGB2) and LTB4 were eluted at
approximately 7 and 11 min, respectively. The LTA4 hydrolase activ-
ity was calculated from the peak ratio of LTB4/PGB2. In a prelimi-
nary study, we have con¢rmed that LTB4 formation was dependent
on the amount of microsomal fraction of the heart samples in this
assay.
2.6. Statistical analysis
Data were expressed as mean þ S.E.M. ANOVA followed by a
multiple comparison test for comparisons on initial data before ex-
pression as a percentage of the control. A value of P6 0.05 was
considered to be statistically signi¢cant.
3. Results and discussion
3.1. E¡ect of ang II infusion on hemodynamics and LTA4
hydrolase expression
Continuous infusion of ang II for 5 and 7 days signi¢cantly
increased the systolic blood pressure and heart rate (Fig. 1A).
Northern blot analysis showed that LTA4 hydrolase mRNA
was signi¢cantly upregulated in the heart of hypertensive rats
receiving ang II (Fig. 1B,C). The detected mRNA size showed
good agreement with that described in the previous report
[12]. LTA4 hydrolase mRNA expression in the heart of nor-
motensive rats had relatively wide variation. This may be due
to the minor contamination of the blood cells in the heart
samples irrespective of the extensive wash-out of the blood.
In any case, upregulation of LTA4 hydrolase mRNA expres-
sion after ang II administration was consistently observed
throughout the study. Subsequently, we carried out Western
blot analysis using a⁄nity-puri¢ed anti-human LTA4 hydro-
lase antibody [13]. As depicted in the previous paper [8,13], an
immunoreactive band of approximately 70 kDa protein, pre-
sumably LTA4 hydrolase protein [12], was detected (Fig. 2A,
left panel). Though another band with the approximate size of
80 kDa was also detected, the identity of this molecule was
unknown. To test the possibility that these two bands origi-
nated from di¡erent cell populations in the heart, protein
samples of cultured cells were also tested. Bands of the
same size were also detected in the cultured vascular smooth
muscle cells (VSMC) and cardiomyocytes of the primary cul-
ture (CMC) (Fig. 2A, right panel), indicating that both
VSMC and CMC have V70 and V80 kDa immunoreactive
proteins. Ang II infusion for 7 days resulted in an approxi-
mately 3.5-fold increase in LTA4 hydrolase protein over the
control. An immunoreactive band at V80 kDa was also in-
creased by ang II infusion, though less markedly. As expected,
LTA4 hydrolase activity was signi¢cantly increased in the
heart of ang II-infused rats (Fig. 3). Compared to the increase
of LTA4 hydrolase protein, increase of its activity was rela-
tively small. This may be partially due to the substrate-de-
pendent irreversible enzyme inactivation of LTA4 hydrolase
[5].
3.2. E¡ects of anti-hypertensive drugs on ang II-induced LTA4
hydrolase upregulation
To investigate the mechanism of ang II-induced LTA4 hy-
drolase upregulation, some rats were given TA-606, a speci¢c
AT1 receptor inhibitor [14], and hydralazine, a non-speci¢c
vasodilator. Both TA-606 and hydralazine e¡ectively normal-
ized the ang II-induced increase in blood pressure. TA-606 did
but hydralazine did not normalize the ang II-induced increase
in heart rate (Fig. 4A). Northern blot analysis showed that
both drugs, when administered to rats not receiving ang II,
Fig. 1. E¡ect of infusion of ang II on the hemodynamics and ex-
pression of LTA4 hydrolase (LTA4H) mRNA. A: Time course of
blood pressure and heart rate of ang II-infused rats (n = 9). B,C: Ef-
fect of continuous ang II infusion on LTA4 hydrolase mRNA levels
in the heart. B: Representative Northern blot analysis. C: Data
from 4^6 animals are summarized in a line graph. *P6 0.05 and
**P6 0.01 vs. sham-operated control.
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slightly decreased the baseline expression of LTA4 hydrolase
mRNA, though this di¡erence was not statistically signi¢cant.
Both drugs suppressed ang II-induced LTA4 hydrolase
mRNA upregulation, suggesting that ang II increased LTA4
hydrolase expression in a pressor-dependent manner.
3.3. Immunohistochemical analysis of LTA4 hydrolase
To examine the localization of LTA4 hydrolase in the heart,
immunohistochemistry was performed. Ang II infusion re-
sulted in the development of an in£ammatory lesion, charac-
Fig. 2. E¡ect of infusion of ang II on expression of LTA4 hydrolase
(LTA4H) protein. Ang II was infused continuously at a rate of 0.7
mg/kg/day for 7 days and the hearts were harvested. Immunoblot
was performed using a⁄nity-puri¢ed anti-LTA4 hydrolase antibody.
A: Left panel, representative immunoblot; right panel, immunoblot
analysis of LTA4 hydrolase using cultured rat VSMC and CMC. In
each lane, two major bands were detected at the sizes of V70 and
V80 kDa. B: Data from 5^6 animals are summarized in the bar
graph. *P6 0.01 vs. sham-operated control.
Fig. 3. LTA4 hydrolase (LTA4H) activity in the heart. After dis-
carding the membrane and microsomal fractions, cytosolic fraction
of the heart from control and ang II-infused rats was prepared and
LTA4 hydrolase activity was determined using high pressure liquid
chromatography. The amount of formed LTB4 was calculated from
the peak ratio of LTB4/PGB2 (see Section 2). Data from 4^5 ani-
mals are summarized in the bar graph. *P6 0.05 vs. sham-operated
control.
Fig. 4. E¡ects of AT1 receptor inhibitor, TA-606 (TA), and non-
speci¢c vasodilator, hydralazine (Hyd), on hemodynamics and LTA4
hydrolase (LTA4H) expression in ang II-induced hypertensive rats.
A: Both TA-606 and hydralazine normalized the ang II-induced in-
crease in blood pressure. However, hydralazine only partially nor-
malized the ang II-induced increase in heart rate. B,C: Both TA-
606 and hydralazine suppressed ang II-induced upregulation of
LTA4 hydrolase mRNA. Though either TA-606 or hydralazine
slightly decreased LTA4 hydrolase mRNA when administered to
normotensive rats, these e¡ects were not statistically signi¢cant. B:
Representative Northern blot. C,B: Data from 4^6 animals are
summarized in the bar graph. *P6 0.05 and **P6 0.01 vs. sham-
operated control rats, respectively.
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terized by granulation tissue formation (increased ¢brosis
(Fig. 5A) and proliferation of K-SM actin positive ¢broblasts
(myo¢broblasts) (Fig. 5B)) and in£ammatory leukocytic in¢l-
tration (Fig. 5C). LTA4 hydrolase was highly expressed in
these in£ammatory lesions. Intense staining of LTA4 hydro-
lase was seen in spindle-shaped myo¢broblasts as well as mi-
grated monocytes/macrophages (Fig. 5D). Intense expression
of LTA4 hydrolase in myo¢broblasts was more obvious in
Fig. 5E. Faint staining of LTA4 hydrolase was seen in the
coronary arteries (Fig. 5G) and cardiomyocytes (Fig. 5I) in
the heart of normotensive rat. LTA4 hydrolase staining in
these regions was more intensely demonstrated in the heart
of hypertensive rats in the same regions (Fig. 5F,H).
In previous experiments, we found that granulation tissue
was formed in the heart of the ang II-induced hypertensive rat
model 7 days after ang II infusion (Ishizaka, N., unpublished
data). In those studies, ang II-induced granulation formation
was inhibited by AT1 receptor blocker (100%) and hydrala-
zine (s 82%). Therefore, both TA-606 and hydralazine may
have suppressed ang II-induced LTA4 hydrolase upregulation,
Fig. 5. Immunohistochemical analysis of the heart of normotensive and ang II-induced hypertensive rats. Ang II was continuously infused for
7 days. A: Masson’s trichrome staining. In£ammatory changes (granulation, ¢brosis) are seen. B: K-SM actin staining. Spindle-shaped non-car-
diomyocytes were strongly K-SM actin positive and, thus, considered to be myo¢broblasts. C: ED-1 staining depicting in¢ltration of mono-
cytes/macrophages in the granulation tissue. D: LTA4 hydrolase staining. In¢ltrated monocytes/macrophages, as well as some myo¢broblasts,
were strongly positive for LTA4 hydrolase. A^D are from the same region of the one specimen and both A-B and C-D are serial sections, re-
spectively. E: LTA4 hydrolase staining of myo¢broblasts. Some of the spindle-shaped, and thus not leukocytic cells, myo¢broblasts were ex-
pressing high levels of LTA4 hydrolase. F^I: Staining of LTA4 hydrolase in the heart from normotensive rats (G,I) and hypertensive rats
(F,H). Increased expression of LTA4 hydrolase was seen in the coronary arteries and cardiomyocytes after ang II infusion.
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at least partially, through inhibiting granulation tissue forma-
tion and in£ammatory cell migration.
Intense expression of LTA4 hydrolase in the myo¢broblast
in the granulation tissue where monocytes/macrophages exist
suggests that the myo¢broblast plays a positive role in recruit-
ing leukocytes and that once leukocytes are recruited, LTB4
will be further generated by intercellular LTA4 transfer from
leukocytes to myo¢broblasts. It was previously suggested that
LTB4 may be an important proin£ammatory mediator of leu-
kocyte invasion into the heart in the setting of myocardial
infarction [15]. Our data also suggested the possible role of
LTA4-LTB4 axis in the pathophysiology of hypertensive heart
disease. Whether or not the LTA4 generating system (by the
successive actions of PLA2 and 5LO) and the LTB4 e¡ector
system are present in non-leukocytic cells with high LTA4
hydrolase expression in the heart should be elucidated in fu-
ture studies.
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